The prophylactic effect of Topiramat and Propranolol on children suffering Migraine

The prophylactic effect of Topiramat and Propranolol on 3-15 years old children suffering migraine in Mofid hospital.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201206133967N2

Enrollment

Registered

2012-12-14

Start date

2012-06-13

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine. Migraine with aura [classical migraine] Migraine: aura without headache basilar equivalents familial hemiplegic with: acute-onset aura prolonged aura typical aura

Interventions

Intervention 1: The control group will receive Propranolol 2-4 mg/kg daily for 2 months. Propranolol is in the form of 10 mg tablets. The name of manufacturer is Hakim Pharmaceutical Company. Interven

Treatment - Drugs

The control group will receive Propranolol 2-4 mg/kg daily for 2 months. Propranolol is in the form of 10 mg tablets. The name of manufacturer is Hakim Pharmaceutical Company.

The intervention group will receive Topiramat 50-100 mg/kg daily for 2 months. Topiramat is in the form of 20 and 50 mg tablets. The name of manufacturer is Arya Pharmaceutical Company.

Eligibility

Sex/Gender

All

Age

3 Years to 15 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: 1-Diagnosis of headache based on international headache criteria 2-Frequencies of 3 or more per month 3-Aging 3-15 years 4-Sever disabling headache Exclusion criteria: Suffering from asthma

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Frequency of migraine attacks. Timepoint: Before, 1 month after and 6 months after treatment. Method of measurement: Observation and interview by the physician followed by filling questionnaire. This questionnaire was designed by researchers of this study.;Severity of migraine attacks. Timepoint: Before, 1 month after and 6 months after treatment. Method of measurement: Observation and interview by the physician followed by filling questionnaire. This questionnaire was designed by researchers of this study.;Duration of migraine attacks. Timepoint: Before, 1 month after and 6 months after treatment. Method of measurement: Observation and interview by the physician followed by filling questionnaire. This questionnaire was designed by researchers of this study.	—

Measure

Time frame

Frequency of migraine attacks. Timepoint: Before, 1 month after and 6 months after treatment. Method of measurement: Observation and interview by the physician followed by filling questionnaire. This questionnaire was designed by researchers of this study.;Severity of migraine attacks. Timepoint: Before, 1 month after and 6 months after treatment. Method of measurement: Observation and interview by the physician followed by filling questionnaire. This questionnaire was designed by researchers of this study.;Duration of migraine attacks. Timepoint: Before, 1 month after and 6 months after treatment. Method of measurement: Observation and interview by the physician followed by filling questionnaire. This questionnaire was designed by researchers of this study.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Ali Khajeh

Mofid Children's Hospital

aliyavar@yahoo.com+98 21 2290 9559

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026